Derek J. Maetzold Sells 2,130 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 2,130 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $19.52, for a total value of $41,577.60. Following the completion of the sale, the insider now owns 78,335 shares of the company’s stock, valued at $1,529,099.20. This trade represents a 2.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Castle Biosciences Stock Up 0.5 %

NASDAQ:CSTL opened at $19.63 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. The company has a market cap of $549.78 million, a PE ratio of 98.15 and a beta of 0.98. Castle Biosciences, Inc. has a 52-week low of $16.97 and a 52-week high of $35.84. The stock has a 50-day simple moving average of $26.17 and a 200 day simple moving average of $28.77.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Mackenzie Financial Corp bought a new position in Castle Biosciences in the fourth quarter valued at approximately $560,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Castle Biosciences by 18.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 66,018 shares of the company’s stock valued at $1,759,000 after purchasing an additional 10,486 shares in the last quarter. Two Sigma Advisers LP bought a new position in Castle Biosciences in the fourth quarter valued at approximately $306,000. Point72 Asset Management L.P. lifted its position in shares of Castle Biosciences by 9.6% in the fourth quarter. Point72 Asset Management L.P. now owns 547,104 shares of the company’s stock valued at $14,580,000 after buying an additional 47,912 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new stake in shares of Castle Biosciences in the fourth quarter valued at approximately $230,000. 92.60% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

CSTL has been the subject of several recent analyst reports. Stephens restated an “overweight” rating and issued a $41.00 price target on shares of Castle Biosciences in a report on Thursday, January 2nd. Robert W. Baird increased their price objective on Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $40.00.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.